A Circulating TLR2 pos CD14 neg CD16 neg “Unclassified Subset” is Decreased in Multiple Myeloma Patients and May Comprise CD163 pos Dendritic Cells

Inside the human bloodstream, a constant patrol of immune cells moves through the veins, acting as the body's early warning system. Among these sentinels are monocytes, a type of white blood cell that acts as a first responder to infection and injury. For decades, scientists have sorted these cells into three distinct groups based on the specific proteins they wear on their surface, much like identifying different types of mail carriers by the color of their uniforms. These groups are known as classical, intermediate, and non-classical monocytes. However, a newer method of identification has emerged, using a protein called TLR2 as a universal flag to catch every single monocyte in one go. This approach promised a cleaner, more complete picture of the immune system, but it also revealed a small, mysterious group of cells that did not fit neatly into any of the three traditional categories. These cells were present in the blood, but their true identity remained a puzzle, leaving researchers unsure if they were a rare type of monocyte or something entirely different.

This uncertainty took on new importance when researchers turned their attention to multiple myeloma, a serious cancer that affects the blood and bone marrow. In patients with this disease, the immune system often struggles to function correctly, failing to recognize and fight the cancer cells effectively. Scientists had previously noticed that the standard groups of monocytes remained stable in number, even as the disease progressed. Yet, when they applied the new TLR2 method to blood samples from patients, they found a discrepancy. A specific population of cells, which they initially called an "unclassified monocyte subset," was significantly lower in patients with multiple myeloma compared to healthy people. The drop was not just a minor fluctuation; it was a clear, measurable difference that suggested these missing cells might be playing a critical role in the body's failed defense against the cancer. The question became urgent: what were these cells, and why did their absence matter?

To solve this mystery, a team of researchers at Aarhus University in Denmark decided to look closer at these unclassified cells. They gathered blood samples from healthy donors and patients with multiple myeloma, using a technique called flow cytometry. This method allows scientists to shine a laser on individual cells as they pass through a machine, reading the unique chemical signatures on their surfaces. The researchers focused on the cells that were positive for TLR2 but lacked the usual markers for the three known monocyte types. They found that these cells carried a protein called CD163, which is typically associated with cells that clean up debris and regulate inflammation. While this protein is found on some monocytes, its presence on these unclassified cells was unusually high, hinting that they might not be monocytes at all.

The team then set out to determine the true identity of this group. By comparing the unclassified cells against known types of immune cells, they discovered that the majority of them were actually dendritic cells. Dendritic cells are a specialized type of immune cell that acts as a bridge between the body's immediate defenses and its long-term memory, teaching other cells how to recognize threats. Specifically, the unclassified cells matched a subset of dendritic cells known as CD1c-positive cells, which are also marked by the CD163 protein. The researchers realized that the new TLR2 method, while excellent at catching monocytes, was also inadvertently catching these specific dendritic cells. This explained why the group was so distinct: it was a mix of two different cell types that had been lumped together because they both carried the TLR2 flag.

The study also revealed that the way scientists choose to sort these cells can change the results entirely. When researchers used a method that simply excluded all other known cell types to find the monocytes, the resulting group was a messy mix containing many different kinds of cells, including only about half dendritic cells. However, when they used the TLR2 method, the group became much cleaner, containing mostly the specific CD163-positive dendritic cells and very few other contaminants. This finding highlighted a crucial point for the scientific community: the tool used to measure the cells determines what is actually seen. The TLR2 method, while efficient, was not just counting monocytes; it was counting a specific, important subset of dendritic cells as well.

The implications for multiple myeloma became clear as the pieces fell into place. The researchers found that the number of these specific CD163-positive dendritic cells was significantly lower in patients with the disease. In healthy individuals, these cells made up a noticeable portion of the blood, but in patients with multiple myeloma, their numbers dropped sharply. This suggests that the immune system's ability to mount a proper defense is compromised not just because of a lack of monocytes, but because of a shortage of these specific dendritic cells. The loss of these cells could explain why the immune system in these patients fails to activate effectively against the cancer. The study did not prove that adding these cells back would cure the disease, but it provided a concrete explanation for a long-standing observation: the immune system in multiple myeloma is missing a key piece of the puzzle.

Ultimately, this research serves as a reminder that the labels we give to biological cells are only as good as the methods we use to find them. By refining how we look at the blood, scientists uncovered a hidden population of cells that had been overlooked for years. The discovery that these cells are actually a specialized type of dendritic cell, and that their numbers drop in a serious blood cancer, opens a new avenue for understanding how the disease progresses. It suggests that future treatments might need to focus on restoring these specific cells to help the body fight back. For now, the work stands as a precise correction to the map of the human immune system, showing that even in well-trodden territory, there are still important landmarks waiting to be found.